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1.1
INDIUM
111PENTETREOTIDE SCINTIGRAPHY IN THE 
DIAGNOSIS AND MANAGEMENT OF NON-IODINE AVID 
CARCINOMA OF THE THYROID. 
J Christian*
1, G Cook
1, C Harmer
1
Royal Marsden Hospital, Downs Road, Sutton, United Kingdom, SM2 5PT
1
The treatment of well-differentiated thyroid cancer has been a success of 
modern medicine with the use of radioiodine (I
131). Follicular and papillary 
carcinoma subtypes may occasionally however be non-iodine avid. The 
medullary carcinoma and the rare Hurthle cell carcinoma (HCC) subtypes are 
characterised by being non-iodine avid. All thyroid tumour types regularly 
express somatostatin receptors subtypes sstr1, sstr3, sstr4, and sstr5[1]. 
Octreotide, an analogue of somatostatin, can be combined with a radioactive 
isotope, (eg Indium
111 Pentetreotide) to visualize tumours with high 
concentrations of somatostatin receptors. We assessed 12 patients with 
histologically proven thyroid carcinoma including 10 patients with HCC (8 
with metastatic disease), 1 with non-iodine avid metastatic papillary 
carcinoma and 1 with locally recurrent medullary carcinoma. In the case of 
metastatic disease the diagnosis was made using conventional radiology 
(CR), ie plain x-ray, ultrasound and computerised tomography. All had 
prospective scintigraphy using In
111Pentetreotide. Out of 8 patients with 
metastatic HCC, 6 had In
111 Pentetreotide positive scans. The sites of 
metastases were correlated with results from conventional radiology and 
shown in Table 1. The two patients with localised HCC underwent 
In
111Pentetreotide scintigraphy as a post operative staging assessment and 
images showed no evidence of residual disease. Both remaining patients with 
medullary or papillary carcinoma had positive In
111 Pentetreotide 
scintigraphy.  
In conclusion In
111Pentetreotide imaging for patients with non-iodine avid 
carcinoma of the thyroid is a useful tool, both for the diagnosis and staging of 
metastases and potentially for treatment purposes. One patient with 
metastatic HCC to bone and a positive octreotide scan has now been treated 
with Yttrium-labelled octreotide.  
Table 1.  The distribution of metastases within the group of patients with 
metastatic Hurthle Cell Carcinoma undergoing scintigraphy with 
In
111Pentetreotide 
Patient 
No. 
Site of metastases 
with conventional 
radiology  
Iodine 
Uptake 
Octreotide 
Uptake 
Octreotide and 
CR correlation 
1  Hilar LNs, lung, 
brain 
Negative Positive  CR  better 
2  Bone, LNs, liver, 
adrenal 
Not 
tested 
Negative N/A 
3  Cervical LNs, lung  Negative  Positive  Concordant 
4  Bony skull base  Negative  Negative   N/A 
5 Residual  thyroid 
disease 
Not 
tested 
Positive Concordant 
6  Mediastinal LNs, 
lung 
Negative Positive  CR  better 
7 Recurrent  neck 
disease 
Negative Positive  Concordant 
8  Bone Negative  Positive  Octreotide 
better  
LNs = lymph nodes    N/A = not applicable 
1.  E.B. Forssell-Aronsson et al, 2000, J Nucl Med 41(4): p 636 
1.2
IN VIVO EVALUATION OF [
18F]FLUOROETANIDAZOLE FOR 
IMAGING TUMOUR HYPOXIA WITH POSITRON EMISSION 
TOMOGRAPHY (PET) 
Henryk Barthel*, Gavin Brown, Hanna Wilson, David R. Collingridge,  
Pat M. Price, Eric O. Aboagye. 
PET Oncology Group, MRC Clinical Sciences Centre, Faculty of Medicine, 
Imperial College of Science, Technology and Medicine, Hammersmith 
Hospital Campus, London, United Kingdom 
Background: Establishing a procedure to noninvasively diagnose tumour 
hypoxia is still a challenge for the medical imaging community. 
[
18F]Fluoroetanidazole ([
18F]FETA) is a new generation radiolabelled 2-
nitroimidazole, which has been designed to overcome the problems 
connected with the first generation PET hypoxia marker, such as slow and 
insufficient uptake. So far, this new radiotracer has not been tested 
systematically  in vivo. Therefore, this present study was initiated. 
Methods: Ex vivo biodistribution studies were performed 1 hour after 
administration of [
18F]FETA into RIF-1 mouse fibrosarcoma, EMT6 mouse 
mammary carcinoma and HT1080-26.6 human fibrosarcoma bearing mice. 
These studies were paralleled by in vivo dynamic PET imaging using a small 
animal scanner. In addition, in the case of RIF-1 tumours hypoxia was 
modulated by carbogen (decrease) and hydralazine (increase) administration. 
In the aforementioned tumour models, independent data on the degree of 
hypoxia were obtained by measuring (1) the radiobiological hypoxic fraction 
by clonogenic assays and (2) the tumour oxygenation using Oxylite probes 
(Oxford Optronix Ltd, UK). 
Results: The table shows the results of the clonogenic assays, Oxylite 
measurements and [
18F]FETA biodistribution studies in the different tumour 
models: 
Tumour Radiobiological  hypoxic 
fraction [%] 
pO2 < 2.5 
mm Hg [%] 
[
18F]FETA uptake 
[%ID/g] 
RIF-1  60.4 – 0.6  49  5.8 – 0.8 
HT1080-
26.6
68.1 – 0.2  57  6.0 – 0.5 
EMT6  78.1 – 4.5  84  7.2 – 0.6 
In the RIF-1 tumour bearing mice, carbogen / hydralazine administration 
resulted in a decrease / increase in the relative frequency of pO2 values < 2.5 
mm Hg in the Oxylite measurements (40 vs. 67 %; p < 0.001); this was in 
concordance with a decrease / increase in the tumour [
18F]FETA uptake (4.9 
– 0.2 vs. 8.1 – 0.6 %ID/g; p = 0.007). The PET imaging data with [
18F]FETA 
were in agreement with the biodistribution studies, but in addition provided 
dynamic information.  
Conclusion: These initial data suggest that [
18F]FETA could by a useful PET 
marker for imaging tumour hypoxia. The technique would be suitable not 
only for primary diagnosis, but also to monitor bioreductive and 
antiangiogenic therapies. 
*Supported by a grant awarded by the Leopoldina Society (Halle, Germany) 
and administered through the German Education and Research Ministry 
(BMBF-LPD 9901/8-22) 
1.3
A RADIATION DOSE RESPONSE EXISTS FOR 
RADIOIMMUNOTHERAPY (RIT) OF B-CELL LYMPHOMA ONLY 
IN THE PRESENCE OF SIGNALLING MONOCLONAL ANTIBODY 
(mAb)  
Y. Du, J. Honeychurch, P.W.M Johnson, M. J. Glennie, T.M. Illidge* Cancer 
Sciences Division, Southampton University School of Medicine, 
Southampton, UK. SO16 6YD 
Radioimmunotherapy (RIT) has emerged as an effective therapy for B cell 
lymphomas. There is however uncertainty whether myeloablative or lower 
(non-myeloablative) radiation doses should be used. We have investigated 
the relative contributions made by mAb and targeted radiation to tumour 
clearance  in vivo and whether a radiation dose response exists for 
radioimmunotherapy. The biodistribution, organ dosimetry and therapeutic 
effect of a panel of 
131I labeled B-cell specific mAbs (anti-CD19, anti-CD22, 
anti-MHCII and anti-Idiotype [Id]) was assessed in two syngeneic murine B-
cell lymphoma models (BCL1 and A31).  Anti-MHCII mAb was estimated to 
deliver the highest total body and tumour-bearing organ radiation dose      (18 
Gy per 18.5 MBq of conjugated 
131I to spleen). In contrast anti-Id, anti-CD19 
and anti-CD22 mAbs delivered significantly less dose to tumour in spleen 
(3.4 Gy, 5.1 Gy, 5 Gy respectively).  
Tumour protection was assessed using the same reagents in the lymphoma 
models following inoculation of 10
6 tumour cells. Treatments were given 
after the development of tumour 10 or 15 days later. Anti-Id and anti-CD19 
but not anti-MHCII mAb demonstrated modest therapeutic efficacy as 
unlabelled mAb in the BCL1model. When conjugated with 18.5 MBq of 
131I, 
all three radioimmunoconjugates provided similar levels of tumour protection 
of around 20 days more than controls.  For radiolabelled anti-MHCII mAb no 
dose response was seen and therapy was the same with either 9.25 MBq or 
18.5 MBq of 
131I. In contrast when unlabelled anti-Id or anti-CD19 was added 
to radiolabelled anti-MHC II a clear radiation dose response was observed. 
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anti-MHC II + anti-Id and over 80% of animals were cured when treated with 
the combination of 18.5 MBq anti-MHC II + anti-Id.  A similar radiation 
dose response was seen in the A31 tumour model with 100 % cures using the 
combination of a radiolabelled mAb and the signalling anti-Id mAb. In 
conclusion we have demonstrated for the first time in vivo that a radiation 
dose response exists for RIT of B-cell lymphoma and that the long term 
clearance of tumour is composed of two components, namely targeted 
radiation and mAb induced cytotoxicity, for which cell surface signalling 
appears important. These findings have important implications for the clinical 
application of RIT for B cell lymphomas. This work was funded by Cancer 
Research UK 
1.4
CAN BOLD MRI BE USED AS A NON-INVASIVE METHOD TO 
INVESTIGATE TUMOUR VESSEL MATURITY USING 
ANGIOTENSIN II?
*KJ Lankester, GM Tozer, SA Hill, RJ Maxwell 
Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middx, HA6 
2JL. 
Introduction: Animal tumour models show a variable response to vascular 
targeting agents, such as combretastatin, which may relate to variable levels 
of blood vessel maturity. Staining of tumour sections for alpha smooth 
muscle actin (α SMA) can be used to assess vessel maturity. Neeman et al.
1
proposed the use of Blood Oxygen Level Dependent (BOLD) MRI during 
periods of air, 5% CO2 and carbogen (5%CO2, 95%O2) breathing as a non-
invasive assessment of vessel maturity. BOLD MRI is sensitive to changes in 
blood flow and/or blood oxygenation due to the intrinsic MR contrast 
provided by deoxyhaemoglobin (deoxyHb). The gas-breathing protocol 
assumes that hypercapnia will result in vasodilatation of mature blood vessels 
(but not immature vessels) and consequent increase in MR signal intensity 
(positive BOLD effect). However, many tumour blood vessels are likely to be 
maximally dilated, so using a vasoconstrictor instead of CO2 might be more 
effective. The purpose of this study was to determine whether using a 
peripheral vasoconstrictor such as angiotensin II (AT) in combination with 
BOLD-MRI can be used to estimate the degree of tumour vessel maturity. 
Methods: The human colon carcinoma, HT29 and the CaNT murine tumour 
were used in mice when approx 350mg. Mice were anaesthetised before 
being placed in a 4.7T Varian MR system. BOLD MRI involved multi-
gradient-echo imaging - 8 echoes; TE 5-40ms, TR 117ms, 4 averages, spatial 
resolution 0.16x0.31x1mm, time resolution 60s. 8 images were obtained 
before treatment, a further 16 images during AT infusion (2µ g/kg/min for 16 
min, i.v.) then another 8 images during recovery. Tumours were excised and 
stained for α SMA. 
Results:  There were no obvious responses to AT in 6/6 HT29 tumours. 
However, in 2/5 CaNT tumours there was a sustained 4% increase in signal 
intensity following the start of AT and a decrease following the end of the 
infusion. Preliminary analysis of the α SMA staining confirmed that CaNT 
has minimal staining and HT29 is more highly stained.  
Discussion:  CaNT has a large response to combretastatin and a minimal 
amount of α SMA staining whereas HT29 has the reverse. A positive BOLD 
response to AT seen in 2/5 CaNT is compatible with the absence of a direct 
vasoconstricting effect on tumour vessels resulting in increased tumour 
perfusion due to the AT-induced rise in systemic blood pressure i.e. it implies 
a lack of mature blood vessels. Tumours with more mature vessels could 
show no BOLD response (as here with HT29) or a negative BOLD response 
if there is an overall reduction in tumour perfusion due to vasoconstriction. 
The pattern of BOLD response is consistent with combretastatin sensitivity 
and α SMA staining in these tumour lines. BOLD has the advantage of 
providing intrinsic contrast, but other MR measures of changes in blood flow 
or volume might give a more direct measure of vessel maturity. 
Reference: 1. Neeman M et al. Magn Reson Med 2001;45:887. 
Funding: Marie Curie Translational Research Fund; Cancer Research UK; 
Gray Cancer Institute. 
1.5
CARBOGEN AND NICOTINAMIDE SELECTIVELY INCREASE 
CHEMOTHERAPY DELIVERY AND BLOOD FLOW TO LIVER 
METASTASIS 
Nishi Gupta, Azeem Saleem, Safiye Osman, Peter Hoskin*, Patricia M Price, 
Eric O Aboagye 
Cancer Research UK, PET Oncology Group, Hammersmith Hospital, Du 
Cane Rd, London W12 ONN, UK 
*Mount Vernon Hospital, Northwood, Middlesex, UK 
Aim: A combination of carbogen (95% oxygen and 5 % carbon dioxide) and 
nicotinamide (C/N) has been shown to improve drug delivery and blood flow 
(BF) in tumours in animals (McSheehy, 1998, Cancer Res, 58, 1185). We have 
measured the effect of carbogen and nicotinamide on 5-FU delivery and 
perfusion in tumour in man, in vivo, using positron emission tomography (PET). 
Method: 6 patients, M/F 3/3, mean age 64 years (range 52-78) receiving 1
st
line De Gramont chemotherapy for metastatic colorectal cancer were studied. 
All patients underwent dynamic PET scanning with (H2[O
15]) prior to and 5-
[
18F]FU concurrently with their 5-FU bolus on 2 cycles of chemotherapy. The 
second PET scan was performed 2-3 hours after ingestion of nicotinamide 
(60mg/kg), with carbogen breathing commencing 5 minutes prior to scan 
start and for 5 minutes after (10 minutes in total). 5-FU delivery was 
calculated using standard uptake value at 3 minutes (SUV3) and BF (ml 
blood/min/ml tissue) and vascular volume of distribution (VD) calculated 
using a 1- tissue compartment model.  
Results: In total, 5-FU, SUV3 blood flow and VD in 10 liver metastasis (> 3 
cm) and the spleen as an example of normal tissue, were evaluated in the 6 
patients: 
Liver metastasis Spleen 
Mean 5 FU SUV3 pre C/N  6.277x10
-5 1.264x10
-4
Mean 5 FU SUV3 post C/N  8.271x10
-5 1.202x10
-4
Mean VD pre C/N  0.78  0.89 
Mean VD post C/N  0.72  0.91 
Mean BF pre C/N  0.2292  1.880 
Mean BF post C/N  0.3369  1.823 
There was a significant increase in 5-FU SUV3 (p=0.0137) and blood flow 
(p=0.0039) to liver metastasis following C/N, with no change in VD. Splenic 
BF, 5-FU SUV3 and VD showed no significant changes after C/N. Arterial 
blood gas analysis showed a mean increase in pO2 from 93mmHg (range 77-
118) to 278mmHg (range 213-319) after 7.5-10 minutes of carbogen 
breathing, and returned to normal 5 minutes after cessation of carbogen 
inhalation. pCO2 and pH remained unchanged throughout. 
Discussion: C/N selectively increases BF and 5-FU delivery in human 
tumours. This system provides a model for the assessment of new agents 
postulated to improve chemotherapy delivery to human tumours. 
This work is supported by a core MRC grant and CRC grants (SP2193/0401, 
SP2193/0202). 
1.6
HOW BEST TO DETERMINE RELAPSE/PROGRESSION IN 
OVARIAN CANCER 
I.M. Hennig*
1, L. Clarkson
2, A. Sanderson
2, G.D. Hall
1, T.J. Perren
1, J.A. 
Spencer
2
Cancer Research UK Clinical Centre
  1  & Department of Radiology
2, St. 
James￿s University Hospital Leeds, LS9 7TF, UK 
Aim: To determine best practice to diagnose progressive disease in patients 
with ovarian cancer. 
Introduction: From 1991 to 1997, 97 patients from Leeds were randomised 
to maintenance interferon or no further treatment following surgery and/or 
induction chemotherapy within a national phase III clinical trial.  Clinical 
follow-up with CA125 levels occurred every two, three, four months during 
the first, second and third year after randomisation, and six monthly 
thereafter.  Routine CT was performed every six months for the first two 
years. 
Methods: Retrospective review comparing clinical data, CA125 results and 
CT scans. This study was approved by the United Leeds Teaching Hospital 
Ethics Committee. 
Results: 84 patients (pts) had complete clinical and radiological data.  2 pts 
developed second malignancies and were excluded from the final analysis.  
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(MN)  All patients:  Progressive disease (PD) occurred in 75 of all 82 pts.  
This was detectable clinically in 27 pts and by ↑  CA125 in 53.  60 of the 70 
MP pts (85.7%) were determined to have progressed by clinical findings 
and/or rising CA125.  Complete remission:  49 pts were in complete 
remission (CR) at trial entry, 7 remain disease free.  Relapse was detectable 
clinically in 11 pts.  30 had rising CA125 levels prior to or at relapse.  3 pts 
with normal markers were diagnosed with PD clinically prior to CT.  Disease 
progression was confirmed by CT in 40 pts (one pt died prior to CT, one had 
no CT evidence of PD).  Median time from elevation of CA125 to 
radiological PD was 44 days.  9 of 42 pts were therefore clinically well with a 
normal CA125 at the time of CT defined PD.  Residual disease:  33 pts had 
residual disease at trial entry (2 pts had only ↑  CA125).  13 had persistent 
elevation of CA125, 20 had a normal CA125.  All 33 progressed (31 with 
confirmation on CT).  PD was detectable in 17 pts by clinical examination 
and 25 had ↑  CA125.  2 pts with normal markers had clinical PD prior to CT.  
Median time from elevation of CA125 to radiological PD was 50 days.  2 of 
the 33 pts were clinically well with a normal CA125 at the time of CT 
defined PD.  Marker negative: 5 of the 9 MN pts achieved a radiological 
complete remission, 1 of these relapsed.  4 MN pts with residual disease on 
CT all progressed radiologically.
Conclusion:  Clinical examination alone is insensitive but when combined 
with the assessment of CA125 is able to detect a significant majority of 
disease progression.  Although this study supports the NCI recommendation 
that routine CT scanning is not indicated in the follow-up of ovarian cancer, 
its role in marker negative patients should be reconsidered.  The added value 
of detecting clinically unexpected findings by CT is subject to ongoing 
studies. 
1.7     
MANAGEMENT OF INTERNAL MAMMARY NODES IN SENTINEL 
NODE  BIOPSY 
Professor R E Mansel* ￿ Principal Investigator on behalf of the ALMANAC 
Trialists Group 
Department of Surgery, University of Wales College of Medicine, Cardiff 
Introduction: Sentinel Node Biopsy (SNB) is a guided technique for 
determining axillary lymph node status of patients with breast cancer.  Whilst 
it is hoped that SNB will eliminate unnecessary surgery for two thirds of 
breast cancer patients who currently receive standard axillary treatment, 
either axillary clearance or axillary sampling, to date there has been no 
detailed evaluation of this new technique in the form of a large randomised 
trial.  One of the issues raised by the SNB technique is the management of 
the internal mammary nodes.  
The ALMANAC trial (Axillary Lymphatic Mapping Against Axillary Nodal 
Clearance) is a two staged, multi-centre trial comparing SNB with standard 
axillary treatment in the management of breast cancer.  The first stage, now 
completed, was an Audit stage where surgeons were evaluated on their ability 
to successfully perform the technique.  The second stage, which is currently 
ongoing, is comparing SNB with standard axillary treatment in terms of arm 
and axilla morbidity, health economics and quality of life.  The Audit stage 
data is presented here. 
Method: In the Audit stage, surgeons performed a sentinel node biopsy 
before going on to perform their standard axillary procedure, either axillary 
sampling or axillary clearance. The sentinel node was localised using a 
combined technique of a radioisotope (Technetium 99m) and blue dye 
(Patent blue V).  In accordance with the ALMANAC protocol the patient was 
either injected with the radioisotope the day before the operation (40MBq) or 
on the day of operation (20MBq).  This was followed by a static 
lymphoscintiscan at least three hours from the time of injection. The drainage 
site was recorded and the number of hot nodes noted. 
Results: In total 29 surgeons took part in the Audit stage and 803 patients 
were recruited. Eight patients did not receive a scan due to logistical 
problems.  Data was missing on a further 26 patients leaving 769 cases of 
analysable data.  There were 206 cases (27%) where no drainage site was 
reported on the scan and 563 cases (73%) where drainage was reported. 
Axillary drainage was reported in 537(70%) cases and internal mammary 
drainage in 63(8%).  Of the 63 patients, only 22(35%) had lymph nodes 
removed of which 2 ￿nodes￿ proved to be fatty tissue. Only 4 patients had 
internal mammary nodes that were pathologically positive and in 2 of the 
patients the axillary nodal status was negative. One patient sustained a 
pneumothorax and one patient suffered bleeding from the internal mammary 
artery. 
Conclusion:  Removing the internal mammary nodes remains a difficult 
routine procedure.  Due to the relatively small percentage of patients that 
have positive internal mammary nodes with negative axillary status (ie have a 
change in stage), we conclude that routine removal of internal mammary 
nodes will have a minimal effect on the mortality from breast cancer. 
2.1
MOLECULES AND MECHANISMS: THE STORY OF PHORTRESS. 
Tracey D. Bradshaw. 
The Pharmacy School, University of Nottingham, Nottingham, NG7 2RD, 
U.K. 
During this presentation, I would like to trace the molecular evolution of 
Phortress, describing elucidation of the mechanism of action of the enigmatic 
class of compounds to which it belongs. I hope to illustrate the interaction 
between chemistry and pharmacology which led to selection of a clinical 
candidate. The synthesis of polyhydroxylated 2-phenylbenzothiazoles, 
designed as potential tyrosine kinase inhibitors, yielded 2-(4-
aminophenyl)benzothiazole (CJM 126). Intriguingly, CJM 126 exerted 
pronounced growth inhibition in breast cell lines only, effecting an unusual 
biphasic dose response. Substitution at position 3 in the phenyl ring with a 
halogen atom or alkyl moiety enhanced potency in the breast carcinoma panel 
and extended the spectrum of exquisitely selective antitumour activity to 
ovarian, renal and colon cell lines (GI50<10 nM). In vivo evaluation 
demonstrated the superior antitumour activity of 2-(4-amino-3-
methylphenyl)benzothiazole (DF 203). Mechanisms of action were unknown; 
remarkably similar profiles of antitumour activity within the series failed to 
COMPARE with any clinical class of chemotherapeutic agent. Crucially, 
only sensitive cells sequestered DF 203, liberating the C-6 hydroxylated 
metabolite (6OH 203). Planar, hydrophobic aminophenylbenzothiazole 
analogues are potent ligands for the cytosolic aryl hydrocarbon receptor. 
CYP1A1 mRNA, activity and protein expression are powerfully induced. 
NADPH-dependent DF 203-derived covalent binding to recombinant 
CYP1A1 is reduced by glutathione, suggesting 1A1-dependent formation of 
(a) reactive electrophilic species.  Indeed, 2-(4-aminophenylbenzothiazole-
derived DNA adducts are generated in sensitive tumour cells only. 
Paradoxically however, 6OH 203 is devoid of antitumour activity. This 
metabolite antagonises cellular uptake of DF 203, covalent binding between 
CYP1A1 and DF 203, CYP1A1 activity and growth inhibition induced by DF 
203. The evidence suggests that CYP1A1-catalysed ring hydroxylation 
underlies the biphasic dose response. To thwart deactivating metabolism, 
fluorinated analogues of 2-(4-aminophenyl)benzothiazoles have been 
synthesised. 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203) 
elicited a conventional dose response; oxidative metabolism at C-6 was 
eradicated. Superior potency in vitro and enhanced efficacy in vivo against 
human breast and ovarian tumour xenografts led to this agent becoming the 
favoured analogue for clinical consideration. To improve drug 
bioavailability, the exocyclic primary amine function of lipophilic 2-(4-
amino-3-methylphenyl)benzothiazoles has been successfully conjugated to 
alanine and lysine residues as mono- and dihydrochloride salts respectively 
yielding water soluble, chemically stable prodrugs. In vitro, selective 
antitumour activity is retained as parent amine is regenerated in the presence 
of carcinoma cells. In vivo, prodrugs rapidly and quantitatively revert to their 
parent amine. Plasma concentrations of 5F 203 regenerated from the 
lysylamide prodrug Phortress, sufficient to elicit cytocidal activity against 
human mammary carcinoma cell lines, persisted > 6h. The growth of breast 
and ovarian xenograft tumours was significantly retarded by Phortress. 
CYP1A1 protein expression and DNA adduct formation, selectively induced 
in sensitive carcinoma cells, has been detected in MCF-7 and IGROV-1 
tumours 24 h after treatment of mice with Phortress (20 mg/kg). Phortress 
will undergo Phase I clinical evaluation in 2002, under the auspices of Cancer 
Research UK. 
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THE HISTONE DEACETYLASE INHIBITOR PXD101 INHIBITS 
THE GROWTH  OF HUMAN OVARIAN AND COLON TUMOUR 
XENOGRAFTS  IN VIVO.
J.A. Plumb*, R.J. Williams
1, P.W. Finn
1, M.J. Bandara
1, M.R. Romero
1, C.J. 
Watkins
1. N.B. La Thangue
1 and R. Brown. 
Department of Medical Oncology, University of Glasgow, Cancer Research 
UK Beatson Laboratories, Glasgow, G61 1BD and 
1Prolifix Ltd, Abingdon, 
OX14 4RY.
Histone deacetylation has a central role in the control of gene expression, 
including transcriptional repression of tumour suppressor genes. Treatment of 
tumour cells with inhibitors of the enzyme histone deacetylase (HDAC) 
results in gene activation, growth suppression and induction of differentiation 
or apoptosis. PXD101 is a novel hydroxamate type inhibitor of HDAC that 
inhibits HDAC activity in HeLa cell extracts with an IC50 in the range 20-
40nM. PXD101 inhibits the growth in vitro of a range of tumour cell lines 
with IC50s in the range 0.3 - 5.7µ M as determined by an MTT assay. The 
pattern of sensitivity in vitro observed for PXD101 in the cell lines is distinct 
from that observed for the HDAC inhibitor oxamflatin and for the DNA 
damaging cytotoxic cisplatin. In contrast, there is a clear correlation between 
sensitivity to oxamflatin and cisplatin (r
2 = 0.7). A concentration-dependent 
(0.2 - 5µ M) increase in acetylation of histones H3 and H4 is observed in 
tumour cell lines including colon, lung, breast and prostate. Furthermore, the 
level of acetylation observed at 0.2µ M correlates with the sensitivity of the 
cell line. Incubation of the human ovarian cell line A2780 with PXD101 
(1µ M) results in acetylation of H3 & H4 within 30 minutes that is retained 
for up to 36 hours with continuous incubation. For oxamflatin, acetylation is 
maintained for only 6 to 8 hours. Following removal of PXD101, acetylation 
is maintained for about 30 minutes but is markedly decreased after 1 hour. 
PXD101 (2µ M) induces apoptosis in A2780 and in the colon cell line 
HCT116 as characterised by PARP cleavage after treatment for 24 hours.  
Treatment of nude mice bearing A2780 tumour xenografts with PXD101 (10 
- 80mg/kg/day intraperitoneally) daily for 7 days causes a significant dose 
dependent growth delay with no obvious signs of toxicity to the mice. 
Growth delay is also observed for xenografts of the cisplatin resistant 
derivative of A2780 (A2780/cp70) and for HT29 and HCT116 colon 
xenografts. A marked increase in acetylation of H4 is observed in blood, 
tumour and skin of mice 3 hours after treatment with PXD101 at 20 and 
40mg/kg. 
Thus the histone deacetylase inhibitor PXD101 inhibits growth and induces 
apoptosis in human tumour cells. The inhibition of growth of human tumour 
xenografts in mice, with no obvious toxicity, suggests that PXD101 has 
potential as a novel anti-tumour agent. Furthermore, measurement of histone 
acetylation in blood or skin could provide a suitable pharmacodynamic 
endpoint to monitor drug activity.
2.3
ANTISENSE DOWNREGULATION OF GENE EXPRESSION IN 
CHRONIC MYELOID LEUKEMIA; DELIVERY COUNTS. 
 O Connor L
1*., Gately K
1., McElwaine S
1., McCann SR
1., Cotter T
2.,
Hollywood D
1., Lawler M
1. Depts 
1Haematology St James￿s Hospital and 
Trinity College Dublin, Ireland, 
2 Biochemistry, University College Cork 
Ireland. 
Chronic Myelogenous Leukemia(CML) is a myeloproliferative disorder 
characterised by a disease specific marker t(9,22) which  gives rise to a 
leukaemia specific RNA (bcr-abl) involving either a fusion of exon 2 of bcr
and exon 2 of abl (b2a2) or exon 3 of bcr and exon 2 of abl (b3a2). Both 
RNAs encode a tyrosine kinase (P210) that makes  CML cells resistant to 
conventional chemotherapy. Bcr-abl could serve as a target for molecular 
directed therapies.  Antisense oligonucleotides (ODNs) are short stretches of 
DNA, approximately 18-20bp in length, with a sequence complementary to a 
specific mRNA. Theoretically, they provide a mechanism for inhibition of 
expression of disease causing genes while leaving the expression of non-
targeted genes unaffected. Antisense ODNs directed against either the b2a2 
or b3a2 breakpoints to downregulate bcr-abl expression were initially tested 
in material from bone marrow donors using both short term (CFU-GM) and 
long term (CAFC) culture assays. These assays indicated that antisense 
ODNs display minimum toxicities against normal haemopoietic stem cells, a 
critical requirement before proceeding to examine the effects on malignant 
cells.   Testing of fluorescently labelled antisense ODNs (by FACs and 
fluorescent microscopy) indicated that they can penetrate CML cell lines 
(K562, KYO1, LAMA 84 and BV 173) and uptake was consistent with fluid 
phase endocytosis. Testing of CML cell lines by western blot analysis 
indicated  downregulation of  P210. However in all cell lines tested, 
downregulation of expression of P210 was variable (10-40%) and transient 
(<24 hours). Primary cells from CML patients (n=4) were treated with 10uM 
antisense for 48 hours and 2/4 exhibited a reduction in CFU-GM colony 
number  (36 ￿ 40%) indicating a specific anti-proliferative effect in CML 
cells. In order to improve downregulation of P210 and enhance antileukemic 
effects,  we examined the kinetics of uptake of antisense ODNs using either 
carrier systems or approaches  that permeablise the cell to antisense delivery.  
A critical component of the antisense approach is its ability to traverse the 
cell membrane whose lipid bilayer  naturally repels the charged antisense 
molecule. Thus successful antisense approaches require an efficient method 
of cellular delivery. We have tested a number of carrier systems including 
different  liposome and dendrimer  formulations which while achieving 
improved uptake (as judged by fluorescent and confocal microscopy of 
fluorescently labelled ODNs) also exhibit significant toxicity to normal cells 
(10-30%). Streptolysin-O(SL-O) is a bacterial toxin, which forms pores in the 
cell membranes of eukaryotic cells by binding to cholesterol. Following 
binding and polymerisation therein, resealing of the pores is then induced by 
addition of  cholesterol containing FCS.  SL-O was the most efficient method 
of delivery of oligonucleotides into the nucleus and cytoplasm, giving uptake 
> 95% in the 4 CML cell lines tested and  cell death was  minimal. Real time 
PCR using TaqMan technology indicated 2-3 log reduction in bcr-abl
transcripts at 24-48 hours. Thus appropriate choice of delivery system can 
greatly enhance the antisense effect in CML cells. Future approaches include 
the selection of antisense ODNs with superior hybridisation properties using 
either morphilino linkages or microarray technology. 
2.4
HA14-1, A SMALL MOLECULE BCL-2 ANTAGONIST:  
CHEMOSENSITZATION AND PHARMACODYNAMICS IN 
LEUKAEMIA 
Dean A. Fennell*, Margherita Corbo, Arben Pallaska, Finbarr E. Cotter 
Department of Experimental Haematology, Barts and The Royal London, 
Queen Mary’s School of Medicine and Dentistry, London, E1 2AD 
Induction of apoptosis is a mitochondrial final common pathway underlying 
the efficacy of cytotoxic therapy for leukaemia, and its inhibition confers an 
important mode of chemoresistance. Bcl-2 is a mitochondrial protein that 
heterodimerizes with, and blocks the action of death agonist homologues Bax 
and Bak, essential for chemotherapy induced apoptosis. HA14-1 is a first 
generation, low molecular weight, organic Bak BH3 peptide mimetic that 
binds Bcl-2 and Bcl-XL, with micromolar affinity, and blocks death agonist 
heterodimerization. Putative synergistic interactions between HA14-1 and 
chemotherapy were therefore investigated quantitatively in HL60, BV173, 
and Bcl-2 transfected K652 leukaemia cell lines. Tolerance distributions for 
HA14-1, VP16 and ara-C induced mitochondrial depolarisation (∆Ψ m
collapse, measured using the amphipathic probe DiOC6(3) and propidium 
iodide), and apoptosis (determined morphologically, and by ZVAD.fmk 
inhibitable loss of plasma membrane lipid packing using MC540 and 7AAD), 
were measured at single cell resolution using flow cytometry, then fitted by 
modified Hill equation using maximum likelihood non-linear regression. 
Fixed ratio combinations of HA14-1 with VP16 or Ara-C yielded concave-up 
(synergistic) isobolograms. Quantitative interaction analysis by the Chou-
Talalay method demonstrated significant synergy (combination index < 0.5) 
in the ED25 and ED75 dose range following exposure for 48 hours. The 
magnitude of the measured combination index was time dependent, synergy 
increasing with the duration of exposure. HA14-1 exhibited significant 
schedule dependence in all of the cell lines studied, with greater cytotoxicity 
being observed for HA14-1 administration pre-chemotherapy, in contrast to 
HA14-1 administration following VP16. Mitochondrial dysfunction and 
apoptosis were induced to a similar degree in Bcl-2 transfected K562 cells 
(that constitutively express Bcl-XL)  compared with vector only transfected 
cells. HA14-1 induced ∆Ψ m collapse occurred within an hour at 25 
micromolar concentration, was irreversible following 30 minutes exposure, 
and was not suppressed by the pan-caspase inhibitor, Z-VAD.fmk. In the 
functional p53 expressing cell line MOLT-4, HA14-1- induced cell death was 
not prevented by the p53 inhibitor pififthrin in contrast to VP16 induced cell 
death, supporting a p53 independent mechanism of cell death. Using real-
time flow cytometry, rapid oxidation of the redox sensitive probe 
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HA14-1, that was not prevented by the superoxide dismutase mimetic 
MnTBAP, nor the mitochondrial permeability transition pore complex 
inhibitor, cyclosporin A. In summary, HA14-1 is a novel small molecule that 
interacts with Bcl-2 or Bcl-XL, and sensitises cells to chemotherapy induced 
cell death. This represents a new lead compound for the development of 
future therapeutic strategies for reversing chemoresistance in leukaemia. 
2.5
CAPTOPRIL INHIBITS THE MATRIX METALLOPROTEINASES: 
MMP-2 AND MMP-9 
RN Williams
1*, RA Dean
1, SL Parsons
3, BJ Rowlands
2, SA Watson
1
1Academic Unit of Cancer Studies, 
2Dept. of Surgery, QMC, University 
Hospital, Nottingham, NG7 2UH; 
3Dept. of Surgery, City Hospital, 
Nottingham 
Background: The matrix metalloproteinases (MMPs) are a family of zinc 
dependent endopeptidases capable of degrading components of the extra-
cellular matrix (ECM). The activity of these enzymes is crucial for lysis of 
the ECM that occurs during tumour angiogenesis, tumour growth and 
metastasis. Angiotensin Converting Enzyme (ACE) inhibitors, such as 
Captopril, inhibit the activity of the zinc dependent metallopeptidase enzyme 
ACE, by binding the zinc moiety of the enzymes active site. The aim of this 
study was to determine whether the ACE inhibitor Captopril could inhibit the 
activity of other zinc dependent enzymes involved in malignant progression, 
namely MMP-2 and -9.  
Methods: Gelatin zymography was used to investigate inhibition of the 
activities of MMP-2 and MMP-9 by Captopril. Conditioned media from the 
human fibrosarcoma cell line HT1080, (known to secrete both MMP-2 and 
MMP-9 in large quantities) was used for zymography following protein 
determination. Captopril was added to the developing buffer for the overnight 
incubation in a range of concentrations. Subsequently, a known quantity of 
HT1080 cells was incubated over night with a fixed volume of serum free 
medium containing differing concentrations of Captopril. Zymography was 
performed without protein determination and the quantity of cells re-counted 
on removal of the media.  
Results:  Captopril inhibited the activity of both MMP-2 and MMP-9 in a 
dose dependent fashion when added to zymography developing buffer.   
MMP-9 (92kDa) was inhibited to 70.7% (p=0.038), 64.8% (p=0.023), and 
46.9% (p=0.002) of control values by 500µΜ , 1mM and 2.5mM Captopril 
respectively. Pro-MMP-2 (72kDa) was inhibited to 72.9% (p=0.007), 72.3% 
(p=0.046), 55.8% (p=0.001), 40.9% (p=0.002) and 27.2% (p<0.001) by 
250µΜ , 500µΜ , 1mM, 2.5mM and 5mM Captopril respectively. Active 
MMP-2 (62kDa) was inhibited to 23.4% (p<0.001) and 9.3% (p<0.001) by 
250µΜ  and 500µΜ  Captopril respectively. The addition of 5mM Captopril to 
cell culture of HT1080 produced inhibition of MMP-9 activity to 65% 
(p=0.017) of control values whilst MMP-2 activity was 66.1% (p=0.016) for 
pro-MMP-2 and 75% (p=0.015) of control values for active MMP-2. 5mM 
Captopril inhibited the proliferation of HT1080 when added to cell culture. 
The population of cells treated with 5mM Captopril was only 84% (p=0.047) 
of the untreated control population. 
Conclusions:  These data demonstrate that the ACE inhibitor Captopril is 
capable of inhibiting MMP-2 and -9. Inhibition of MMP activity by Captopril 
added to zymogram developing buffer suggests that Captopril inhibits MMPs 
by binding their active site. The inhibition of MMP activity produced by the 
addition of Captopril to cell culture is greater than its inhibitory effect on cell 
proliferation. This suggests that Captopril may inhibit other cellular pathways 
and that the reduction in MMP activity is not only a reflection of the 
reduction in cell population.  
2.6
INHIBITORY EFFECT OF NOVEL NON-PEPTIDE 
CHOLECYSTOKININ ANTAGONISTS ON GROWTH OF HUMAN 
GLIOMA CELLS IN CULTURE 
Eftychia Oikonomou*, Eric Lattmann and Eric F Adams, Pharmaceutical 
Sciences Research Institute, Aston University, Aston Triangle, Birmingham 
B4 7ET, UK. 
Gliomas are very serious brain tumours with life expectancy after diagnosis 
averaging only nine months. Their inaccessible location and / or adherence to 
surrounding structures often hinder complete removal of these tumours by 
neurosurgical procedures. It is therefore desirable to develop improved 
adjuvant medical therapies which are able to strongly inhibit or eliminate 
residual tumour growth thereby reducing the chances of recurrence. Previous 
studies have demonstrated that the gut-brain peptide, cholecystokinin (CCK), 
is able to powerfully stimulate growth of rat glioma cells in-vitro (1). It might 
therefore be anticipated that blockade of CCK receptors will have an 
inhibitory effect on glioma cell mitosis. We have developed a number of non-
peptide asperlicin CCK antagonists and examined their effects on growth of 
human glioma cells in culture. Cells were seeded at a density of 1 x 10
5 per 
flask and grown in the presence of varying doses (0-20 µ mol / L) of two of 
these novel compounds, HSH and 7.4.5, for up to two weeks. After this 
period, cells were removed from the flasks by trypsinisation and their number 
determined by means of a Coulter Counter. Both compounds strongly 
inhibited growth of the human glioma cells by up to 80% in a dose-dependent 
manner. In addition, the stimulatory effects of epidermal growth factor on 
glioma cell growth was completely abolished by co-incubation with each of 
the CCK antagonists. A time course study revealed that these inhibitory 
effects remained consistent for at least two weeks in culture. The results 
suggest that CCK antagonists are able to inhibit human glioma cell growth. 
Because of their non-peptide nature, it may be possible to further develop 
these compounds as orally active anti-glioma drugs. 
1)  Kaufmann R et al (1998) Protein kinase C is involved in 
cholecystokinin octapeptide-induced proliferative action in rat glioma cells. 
Neuropeptides 32: 185-189. 
2.7
ACTIVITY OF CRE-DECOY OLIGONUCLEOTIDES IN 
COLORECTAL CANCER CELL LINES. 
WM Liu*, KA Scott, SP Joel and DJ Propper. 
Dept Medical Oncology, St Bartholomew’s Hospital, London. 
The cAMP response element (CRE) consensus sequence directs the 
transcription of a wide range of genes. A 24-mer ss oligonucleotide sequence 
has been shown to compete with these sequences for binding transcription 
factors and therefore interferes with cAMP-induced gene transcription. We 
have examined the cytotoxic effect of this CRE-decoy oligonucleotide (CDO) 
alone and in combination with a range of chemotherapeutic drugs in 
colorectal cancer cell lines. Cell viabilities and cell cycle distributions were 
assessed daily throughout a 4-day treatment schedule, and in cells treated for 
4-days followed by drug-free medium. CDO was an effective cytotoxic agent 
when used alone in HCT116 and GEO cell lines (IC50: 0.29 µ M and 0.36 µ M
respectively), but ineffective in SW620 cells (viability > 85% at all time 
points with CDO up to 1.6 µ M). Control oligonucleotides had no effect of 
cell proliferation and viability. Loss of viability in the sensitive cells was 
associated with increases in p21
waf1 and bax protein expression, but with no 
change in bcl-2 levels. Flow cytometric analysis indicated increased 
apoptosis (A) with concomitant reduction in cells in the G1-phase of the cell 
cycle (day 4 %A and %G1: 19.8 ±  1.0 and 26.1 ±  1.6 vs. 2.5 ±  1.0 and 45.6 ±
2.5 respectively in control cells; all p<0.001). The combination of CDO with 
existing chemotherapy resulted in additive cell kill. However, there were 
synergistic reductions in total cell number, which were small but consistent 
(the table shows results from the cultures with each drug at IC25 in HCT116). 
cells 
(x10
6/ml) 
5-
fluorouracil 
Oxaliplatin Mitomycin Etoposide 
Observed  -20.9  ±  3.9  -18.1 ±  4.6  -17.1 ±  2.8  -9.3 ±  1.7 
Estimated  -16.4 ±  4.6*  -13.9 ±  7.4*  -15.4 ±  2.9  -6.6 ±  2.0* 
Estimated values are the calculated sum of the reduction in cell numbers 
from separate CDO and drug cultures. *p<0.01 vs. observed value. 
Data also indicated that the re-culture of CDO pre-treated cells in drug-free 
medium resulted in continued cell kill and apoptosis even in the absence of 
drug. Notably, this extent of cell kill was actually greater than that seen in the 
cultures maintained in CDO. This was demonstrated most clearly in GEO 
cells where there was nearly a two-fold increase in apoptosis (%A: 4-days 
CDO + 4-days in drug-free medium: 31.3 ±  1.6% vs. 19.8 ±  1.0% in cells 
treated with CDO for 8-days; p<0.001). These results confirm the cytotoxic 
effect of CDOs in vitro, and also highlight the schedule-dependent nature of 
its activity. Studies are on going to elucidate the relationship between CDO 
cytotoxicity and cell cycle regulation. 
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TUBULAR CARCINOMA OF THE BREAST: IS THE LONG TERM 
SURVIVAL  ASSURED? 
A Bashorun*
1, N Beechey-Newman
1, K Ryder
2 and AE Young
1
1.Breast Unit, Guy￿s Hospital, London SE1 9RT.UK 
2.ICRF , Guys Hospital, London SE1 9RT. UK. 
Aims Pure tubular invasive carcinoma (TC) of the breast (Grade I and more 
than 90% tubular formation) is thought to have favourable prognosis in 
treated patients observed over short and intermediate periods of 5-10 years.  
There is, however, little data relating to more extended follow up. This study 
aimed to review the long term (20-25 years) survival of patients with pure 
tubular  carcinoma and to investigate whether this lesion does confer a better 
survival compared with the control group of other commoner grade I invasive 
ductal carcinomas of no   
specified type, (NST).
Materials and Methods Case records from 1975 ￿ 2000 were obtained for 
all grade I invasive ductal carcinomas (NST and TC) treated at Guy￿s 
Hospital London.    
There were 73 patients with pure TC and 420 grade I (NST).  These cohorts 
were of similar age (TC median 52 years (35-83); G1 (NST) median 55.1 
years (27-88). The mean follow up was 9.7 years.  All patients had 
tumourectomy and complete axillary dissection.  Kaplan-Meier survival 
curves were compiled and statistical analysis was carried out  using the Log 
Rank method. 
Findings  There was no correlation between histological type and age 
(p=0.102) or nodal status (p=0.205). In the TC group survival was 
significantly better in patients without lymph node metastasis (p=0.0412).  
No significant statistical differences in long-term survival of patients with TC 
and those with G1 (NST) were identified (P = 0.487).  Moreover the 
similarity in overall survival remained after sub-division into node negative 
(p= 0.23) and node positive (p=0.70) groups.   
Conclusion  Although pure tubular carcinoma has been thought to be a 
favourable  sub-type of breast cancer, it is concluded that its overall long 
term survival is no better than that of the commoner grade I invasive 
carcinoma of non-specific type. Therefore tubular carcinoma should continue 
to be regarded as potentially life threatening in the longer term and 
accordingly should not merit an attenuated  treatment or follow up protocol.  
3.2
WEIGHT LOSS AND ANAEMIA ARE POOR PROGNOSTIC 
FACTORS FOR PATIENTS WITH LUNG CANCER RECEIVING 
CHEMOTHERAPY ￿ WILL MODIFICATION OF THESE 
PROGNOSTIC FACTORS BECOME A NEW STANDARD OF CARE? 
Paul J Ross*, Justin S Waters, Sue Ashley, Kathy Priest, Alison Norton, Tim 
Eisen, Ian E Smith, Mary ER O￿Brien. Lung Unit, Royal Marsden Hospital, 
Sutton, Surrey, SM2 5PT 
This study aimed to examine whether weight loss at presentation influences 
outcome in patients receiving chemotherapy for small cell (SCLC) and non-
small cell lung cancer (NSCLC).  A multivariate analysis was performed on 
data collected prospectively from 1994-2001. Data were available for 
histology, stage, performance status, response, toxicity, progression-free and 
overall survival.  Weight loss at presentation was reported by 59% of 290 
patients with SCLC and 58% of 418 patients with NSCLC.  Patients with 
weight loss and NSCLC more frequently failed to complete at least 3 cycles 
of chemotherapy than patients without weight loss (p=0.003).  Anaemia as a 
toxicity occurred significantly more frequently in patients with NSCLC and 
weight loss (p=0.0003).  No differences in other toxicities were observed.  
NSCLC patients with weight loss had more symptoms at presentation 
(p<0.0001) and were less likely to have a symptomatic response (p=0.001).  
In addition, there was a trend towards fewer symptomatic responses in 
patients with weight loss and SCLC (p=0.06).  Overall survival was reduced 
in patients with weight loss and SCLC (8 months v 11 months; p=0.0003) 
and NSCLC (6 months v 9 months; p<0.0001).  Similarly, progression-free 
survival was shorter in patients with weight loss for both SCLC (6 months v 
7 months; p=0.004) and NSCLC (4 months v 6 months; p=0.01).  In 
multivariate analyses performance status and stage were the most important 
predictors of progression-free and overall survival.  However, weight loss 
remained an independent predictor of shorter overall survival for patients 
with SCLC (p=0.003, relative risk=1.5) and NSCLC (p=0.009, relative 
risk=1.33) and an independent predictor of shorter progression-free survival 
in patients with SCLC (p=0.01, relative risk=1.43).  Patients with NSCLC 
whose weight stabilised during chemotherapy had better overall survival than 
patients who continued to lose weight (p=0.0004). 
Weight loss is an early symptom of lung cancer and predicts for toxicity from 
treatment, in particular anaemia, and shorter survival.  We had previously 
observed that 86% of patients receiving chemotherapy for SCLC and NSCLC 
experienced a nadir haemoglobin < 12g/dL (Waters et al, 2002.  J Clin Oncol; 
20: 601).  In addition, survival was shorter for patients with a nadir 
haemoglobin <12 g/dL (9 months) compared to those with haemoglobin ≥  12 
g/dL (12 months; p=0.001).  We conclude that a trial evaluating nutritional 
supplements combined with correction of anaemia in patients receiving 
chemotherapy should be considered.  Such interventions may improve quality 
of life and possibly survival in lung cancer patients and may lead to a new 
term ￿total supportive care￿. 
3.3
IMPACT OF HAEMOGLOBIN LEVEL ON TREATMENT 
RESPONSE IN PATIENTS WITH ANAL CARCINOMA  
G Hutchison*,
1 AG Renehan,
1 E Levine,
2 R D James,
2,3 ST O￿Dwyer.
1
Departments of 
1Surgery and 
2Clinical Oncology, Christie Hospital, 
Manchester, UK. 
3Present address: Kent Cancer Centre, Maidstone, UK. 
Introduction: Radiotherapy –chemotherapy is the mainstay of treatment for 
anal carcinoma but local recurrence rates requiring salvage surgery remain 
high (30-40%). In more-radiocontrollable tumours an increase in the hypoxic 
cell fraction is associated with treatment-time anaemia and poor outcome 
(1,2). We have evaluated this in patients with anal cancer. 
Methods: Between 1988 and 1998 at the in a single institute, 206 patients 
with anal squamous cell carcinoma were treated with curative intent using 
radiotherapy alone(RT: n=113) or chemoradiotherapy (CRT:  n=93). 
Haemoglobin(Hb) levels before and during treatment were collected, and the 
nadir (lowest values) Hb calculated. Treatment failure was determined 
histologically within twelve months of initial therapy. Univariate (Kaplan-
Meier) and multivariate (Cox proportional hazard) analyses were used with 
Hb levels treated as categorical variables (cut-point: medians by gender). 
Results: Persistent local disease occurred in 37% of cases. There was a non-
significant trend toward decreasing Hb with increasing stage (T1: 12.8g/dl; 
T4 11.8g/dl, K-W: P=0.11). In RT patients, nadir Hb values below the 
median (males: 12.7g/dl; females: 11.9g/dl) were highly predictive for failure 
(Kaplan-Meier, P<0.001). This remained significant after adjustments for 
stage, age and sex (hazard ratio: 6.20,2.86,1.32, CI 95%). No association was 
evident with CRT. 
Conclusion: In patients with anal squamous cell carcinomas, nadir Hb level 
is predictive of response to RT alone but not chemoradiotherapy. These 
findings justify further studies into the role of anaemia in tumour radio-
resistance. 
(1) Hockel M et al. Cancer Res 1999;59:4525-8. 
(2) Henke M et al. Int J Radiat Oncol Biol Phys 2000;48:339-45. 
3.4
hTERT GENE EXPRESSION IS REGULATED BY ALTERNATIVE 
SPLICING OF mRNA DURING THE COURSE OF CML, AND 
TELOMERE LOSS AT DIAGNOSIS IS ASSOCIATED WITH EARLY 
PROGRESSION.  
MW Drummond*
1, S Hoare
2, MJ Alcorn
1, A Monaghan
2, S Graham
1, WN 
Keith
2, TL Holyoake
1.
1ATMU, University of Glasgow, UK; 
2Beatson 
Institute, Garscube, UK. 
Background: Chronic myeloid leukaemia (CML) is characterised by myeloid 
expansion, subsequent to acquisition of the Philadelphia chromosome (Ph). 
Telomere shortening has been demonstrated in peripheral blood leucocytes 
(PBL) of CML patients. Short telomeres in chronic phase disease (CP) have 
been shown to predict for early disease progression, perhaps due to early cell 
￿crisis￿ and acquisition of further mutations. The regulation and role of 
telomerase (in particular the catalytic component, hTERT) during early 
disease remains poorly understood. We prospectively studied newly 
diagnosed CML patients with regard to degree of telomere loss and outcome, 
and examined levels of hTERT mRNA and its splice-variants in samples 
from all stages of CML.  Methods: Flow-FISH telomere measurement of Ph-
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